
|Articles|November 20, 2014
Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma
Author(s)Nicholas Butowski, MD
Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
Advertisement
Clinical Pearls
Nicholas Butowski, MD, associate professor, University of California, San Francisco, neuro-oncologist, UCSF Medical Center, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.
- 1-3 catheters co-deliver liposomal-irinotecan and gadolinium into a patient’s tumor.
- Gadolinium is used so that imaging can be done in real-time.
- This process is unique because it bypasses systemic toxicity and ensures that the drug is administered properly.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma
2
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
3
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
4
FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer
5



































